The follow-up excision (FUE) 
The follow-up excision (FUE) Papillary lesions of the breast comprise a heterogeneous group, including benign, atypical, and malignant disease, 1 and are initially diagnosed with core needle biopsy (CNB) in most cases. The general consensus is that surgical excision is required when any atypical or malignant papillary lesion is detected with CNB. However, the management of a benign papillary lesion or intraductal papilloma remains controversial. The major concern is that an area of atypia or malignancy inside the papilloma or nearby may be missed given the limited sample evaluated with CNB. The upgrade rate varies from 0% to 29%. Some authors recommend surgical excision for all papillomas detected on CNB because of the high upgrade rate to carcinoma in their studies, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] whereas others did not find many upgraded cases. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] However, almost all of these studies were retrospective, involved a small number of cases, and the criteria for the subsequent surgery differed among institutions. A potential bias was seen in patient selection. Because intraductal papilloma is the most common papillary lesion of the breast, accounting for up to 5% of benign mammary disease, appropriate treatment of these patients would benefit both patients and the healthcare system. The goal of this study is to review a relatively large number of cases diagnosed on CNB as intraductal papilloma at Magee-Womens Hospital of the University of Pittsburgh Medical Center (Pittsburgh, PA) from 2005 to 2010 to characterize cases upgraded pathologically as well as radiologically. In our practice at Magee-Womens Hospital, all patients diagnosed as having a papilloma are recommended to undergo surgical excision. To our knowledge, this is the largest retrospective study from a single institution.
Upon completion of this activity you will be able to:
• list risk factors associated with upgrading of intraductal papilloma diagnosed on needle core biopsy.
• discuss the role of histologic and radiologic findings to guide subsequent management.
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Materials and Methods

Patient Selection
This study was approved by the institutional review board of the University of Pittsburgh. A pathology database search was performed at Magee-Womens Hospital for a period of 72 months (January 2005 to December 2010). During this time, 14-gauge needles were mostly used in ultrasound-guided biopsy with 3 to 5 passes. In some cases, 12-gauge needles were used. For magnetic resonance imaging (MRI)-or stereotacticguided biopsy, 9-gauge needles were used with 6 to 9 passes. Biopsy specimens were received in containers with formalin. If calcifications were found on imaging, the specimens were put in separate containers and labeled as such. Tissue cores were embedded in paraffin. Sections in 5 levels were stained with H&E. Surgical excision specimens were fixed in 10% formalin, in most cases submitted entirely and stained with H&E.
Intraductal papilloma was diagnosed for a well-defined encysted papillary lesion with delicate fibrovascular cores covered by a layer of myoepithelial cells and overlying luminal epithelial cells ❚Image 1A❚ and ❚Image 1C❚. Cases were considered to be upgraded if follow-up excision (FUE) showed ductal carcinoma in situ (DCIS) or invasive carcinoma (IC) ❚Image 1B❚ and ❚Image 1D❚. A total 18,361 cases of CNB were performed during the study period. Of these cases, 576 (3.1%) were interpreted as intraductal papilloma with or without other benign or malignant lesions. FUE was performed in 464 (80.6%) cases. Medical records were reviewed for patient age, ethnic origin, personal or family history of breast cancer, associated symptoms (ie, palpable mass, nipple discharge). Ninety-four cases (20.3%) were excluded from the study because of a history of prior (n = 65) or synchronous malignancy (n = 3) or atypical ductal hyperplasia (ADH) and/or lobular neoplasia (LN) (n = 26) in the ipsilateral or contralateral breast, leaving a total of 370 cases in the study. Surgical pathology reports of all lesions were reviewed. The slides of all cases upgraded to DCIS or IC on FUE were reviewed by 2 pathologists (C.Z. and X.L.) to confirm the diagnosis. In most cases (352/370, 95%), multimodal imaging results were available, including mammography, ultrasonography, and MRI, which were independently reviewed by a radiologist (O.W.). CNB was performed with ultrasound guidance in 88% of cases, with MRI-guidance in 6% and stereotactic guidance in 6% of cases. Mammography showed a mass lesion or asymmetry in 45% of cases and associated calcifications in 13.4% of cases. Ultrasonography showed a hypoechoic lesion in 59% of cases and a papillary lesion in 24% of cases. Five percent of the lesions were seen on MRI only. The distance of the lesion or the biopsy clip from the nipple was measured, and The American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) score was recorded for each case.
Statistical Analysis
Data were entered using Microsoft Excel spreadsheet software (Microsoft, Redmond, WA). Mean, median, and standard deviation were calculated. Student t test was performed to test the difference in age between patients who had microcalcifications and those who had no calcifications. Fisher exact test was used to compare the upgrade rate of the 2 groups. A logistic regression analysis was conducted to assess the association of microcalcifications with the upgrade rate adjusted for age. All the analyses were done using the SAS 9.3 system (SAS Institute, Cary, NC), and a P value of less than .05 was considered statistically significant.
Results
The mean age of patients in this study was 51.0 (range, 12-86) years. One hundred ninety-one (51.6%) of 370 patients were 50 years or older. Of these, 77.0% were white, 19.5% were black, and 3.5% were of other ethnicities. Among these lesions, 55.7% were from the left breast, 43.2% were from the right breast, and 1.1% were bilateral.
Fifty-nine percent of patients presented with mammographic abnormalities. Of these, 23% had nipple discharge; 18% presented with palpable masses. The majority of patients (98.6%; 345/350) were rendered a BI-RADS score of 4 (suspicious for malignancy) on mammography before the CNB. Microcalcifications were detected in 13.4% (47/352) of patients on imaging. Radiologic lesions were subdivided into 3 categories: mass lesion seen on mammography and papillary or hypoechoic lesions on ultrasound imaging. The mean size of mass lesions on mammography was 10.7 mm (range, 3-36 mm). The mean size of papillary lesions on ultrasonography was 8.7 mm (range, 3-30 mm). The mean size of hypoechoic lesions on ultrasonography was 8.4 mm (range, 1-50 mm). The average distance of the lesion (marked by a metallic clip) to the nipple was 3.9 cm. The location of the lesion was divided into those within 2 cm from the nipple and those more than 2 cm from the nipple. Twenty-eight percent of lesions were located within 2 cm from the nipple. The time frame between the CNB and FUE ranged from 0.2 month to 15.5 months (mean, 1.96 months). More than 95% of patients had needle localized excisional biopsy or segmental mastectomy in the subsequent surgery.
Significant lesions on FUE were divided into 4 categories: IC, DCIS, ADH with or without LN, and LN alone, which included atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) ❚Table 1❚. Forty eight of 370 cases (13%) were found to have ADH, including 8 cases of atypical papilloma, 8 cases of atypical papilloma with surrounding ADH, and 32 cases of ADH in the surrounding tissue. One invasive ductal carcinoma (0.3%) was found in the subsequent excision. Six cases (1.6%) were upgraded to DCIS including 1 case of pleomorphic LCIS. The total upgrade rate for IC, DCIS, and pleomorphic LCIS was 1.9%.
The slides of all cases upgraded to DCIS or IC on FUE were reviewed by 2 pathologists to confirm the diagnosis. The case that was upstaged to invasive ductal carcinoma had Microcalcifications were found in 51 (13.8%) of 370 cases under the microscope in CNB specimens, of which 4 cases did not show microcalcifications on imaging. These microcalcifications were located either inside or outside the papilloma in the surrounding breast tissue. Of patients with microcalcifications seen on CNB and imaging, 11.8% (6/51) had DCIS or invasive ductal carcinoma on FUE. However, among patients without microcalcifications, only 1 case was upgraded to pleomorphic LCIS (0.3%, 1/319), and no DCIS or IC was found on FUE. The presence or absence of microcalcifications was statistically associated with subsequent upgraded diagnosis (P = .003). All 6 cases upgraded to DCIS or IC on FUE showed microcalcifications on imaging and CNB specimens. Three cases had microcalcifications inside and outside the papilloma, and 3 cases had microcalcifications only in the surrounding breast tissue outside the papilloma (Table 2) .
On subsequent excision, no papillomas were detected in 52 (14.1%) of 370 cases, which probably indicates that these small papillomas were removed during the CNB procedure. The diagnosis of intraductal papilloma was confirmed in 297 cases (80.3%) on subsequent excision, and 21 cases (5.7%) were upgraded to atypical papilloma. All significant lesions (ADH, DCIS, and IC) detected on FUE were from the surrounding tissue of the papilloma.
Patients with papillomas that were upgraded to ADH, LN, or malignancy on FUE were significantly older than those with papillomas that were not upgraded (mean age, 50.1 years vs 57.6 years; P < .001). The average age of patients who had papillomas that were upgraded to malignancy was much older (64.4 years). Five of 7 patients in this group were older than 50 years. Given that more older patients were observed in the microcalcification group (mean age, 56.0 vs 50.8, P = .005) and age could be a risk factor for upgrading to cancer, a multivariate analysis adjusted for age was performed. The result confirmed that microcalcifications were associated with upgrading cancer, independent of age (odds ratio = 32.7; 95% confidence interval = 3.8-282.7; P = .002).
The size of the lesion on imaging, however, was not significantly different between the group with upgrading and that without upgrading, and neither was the distance of the lesion from the nipple ❚Table 3❚.
Discussion
The management of intraductal papilloma detected on CNB has undergone major changes. It was considered malignant many years ago and treated with simple or radical mastectomy. But recognition of its benign nature has led to local excision as the treatment of choice. 1 Now that its clinical behavior is even better understood, some authorities recommend close follow-up instead of surgical intervention if imaging studies are concordant with the clinical and pathologic findings and no other risk factors are found ❚Table 4❚. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Others, however, still recommend surgical excision of intraductal papilloma lesions ❚Table 5❚. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The concern is that atypia or malignancy may be missed with the limited CNB. This is disputed by some radiologists who believe that ultrasound-guided CNB detects benign papillomas accurately, 12, 22 especially with the recent introduction of vacuum-assisted large-volume "mammotome" biopsies. Besides a potential increase in diagnostic accuracy, this method may lead to definitive therapy by removing the entire lesion. 21, 24, 25 In our study, most intraductal papilloma lesions (88%) were detected with ultrasound-guided CNB. All malignant lesions (DCIS and IC) found on FUE were initially detected via ultrasoundguided CNB. At our practice, most ultrasound-guided CNBs were performed using a 14-gauge needle with spring-loaded biopsy gun (Bard Magnum, Bard, Covington, GA) with 3 to 5 passes. Both MRI-and stereotactic biopsies (6% for each method) used 9-gauge Suros ATEC vacuum-assisted needles (Hologic, Bedford, MA) with 6 to 9 passes, which were similar to those used with the Mammotome instrument (Devicor Medical Products, Cincinnati, OH). The smaller-gauge needles with fewer passes might contribute to the upgrading. However, all the malignant lesions were from the surrounding tissue of the papillomas. ADH in the surrounding tissue was found in 32 of 370 cases with or without LN. LN alone was found in 7 cases. Atypical papilloma with surrounding ADH was found in 8 cases and atypical papilloma alone in 8 cases. The overall proportion of cases upgraded to ADH (13.0%) was similar to the average of previous reports (12.1%) ( Table  4 and Table 5 ). However, a finding of ADH or LN on excision did not prompt further clinical intervention except for close follow-up.
Another issue is the diagnostic accuracy of the pathologists. Diagnosis of papillary lesion of the breast is challenging, especially on CNB. A recent study investigated the interobserver agreement between specialized breast pathologists and nonbreast pathologists. 26 Although the agreement between these 2 pathologist groups was "fair," nonbreast pathologists tended to underdiagnose and overdiagnose papillary lesions on CNB. Four of 8 cases that were upgraded to malignancy on excision were initially misinterpreted as intraductal papilloma by nonbreast pathologists. Immunohistochemical staining may be helpful in improving the diagnostic accuracy of papillary lesions. 18 Most pathologists in our institution are specialized for women's diseases with many years of experience in breast pathology. Some had subspecialty training in breast pathology. All cases that were upgraded to malignancy were reviewed by 2 breast pathology specialists (C.Z. and X.L.).
In the previous studies shown in Table 4 , 7 (2.1%) of 329 patients with intraductal papilloma on CNB had breast cancer on FUE, while 101 (10.2%) of 990 patients with intraductal papilloma on CNB had breast cancer on FUE based on other studies presented in Table 5 . The upgrade rate to DCIS, pleomorphic LCIS, or IC (1.9%) in our study was similar to that in the first group of studies and much lower than the second group of studies. A number of factors may explain the significant variation in cases upgraded to breast cancer (0%-29%), such as the case numbers and study case selection. For instance, we excluded all cases with a prior or synchronous malignancy or high-risk lesions (ADH, ALH, LCIS) after a careful clinical history search. There was also no selection bias for subsequent surgery in our study. All patients diagnosed as having intraductal papilloma on CNB were recommended for surgical consultation regardless of symptoms and imaging findings at our hospital. Our FUE rate was 80.6%. To our knowledge, this study represents the largest number of reviewed cases from a single institution. In previous large studies with more than 100 cases, the excision rate was only 50% or less, 3, 6, 12 and decision making mostly depended on patient and physician preferences. 6, 12 The recent study by Rizzo and colleagues 11 involving a relatively large number of cases from 3 different institutions in Atlanta, GA, had an excision rate of 73.4%. Their upgrade rate to malignancy was 8.9%. The majority of the patients in this study were black. However, our patients were mostly white women. Whether racial difference could affect upgrade rates requires further study. Interestingly, in some studies, including 1 prospective study with few patients in which surgical excision was recommended for all, the proportion of cases that upgraded to DCIS and IC was also low. 20, 22, 23 Similar to most previous reports, our study also showed that the rate of DCIS and IC identified on FUE in cases of atypical papilloma on CNB (6/54 cases, 11.1%) was significantly higher than that seen in intraductal papilloma cases (7/370 cases, 1.9%) (P = .0042). In addition to atypia, advanced age (>50 years) or lesion size (>10 mm) appeared to be significantly associated with malignancy on subsequent surgical excision. 7, 11, 12, 20, 27 In our study, patients with atypical papilloma were significantly older than those with intraductal papilloma (data not shown). Patients with intraductal papilloma who were found to be upgraded to ADH or malignancy were also significantly older than those who were not upgraded. No significant difference was seen in tumor size on radiologic imaging between cases with or without subsequent upgrading.
Central papillomas arose in the large mammary duct (collecting duct or lactiferous duct), mostly located within 2 cm from the nipple, whereas peripheral papillomas arose from the terminal duct lobular unit, mostly located more than 2 cm from the nipple. Peripherally located papillomas have been reported to be associated with an upgraded diagnosis on excision. 12 In our study, no difference was found in the distance of the papilloma from the nipple between the cases that were upgraded to ADH or malignancy and those that were not upgraded on FUE (4.1 cm vs 3.8 cm), even though more lesions were located within 2 cm from the nipple in the cases with no subsequent upgrading (30% vs 23.8%). Two other studies have demonstrated similar findings. 22, 28 Lewis et al 29 from the Mayo Clinic (Rochester, MN) conducted the largest cohort study on the risk of breast cancer in women with papillomas. They concluded that patients with a solitary intraductal papilloma had a relative risk of cancer similar to those with proliferative fibrocystic breast lesions without atypia (2.04 vs 1.90) and that the risk could be bilateral.
Intraductal papilloma may have the potential risk of being upgraded to malignancy, and controversy regarding its management continues. Therefore, identification of risk factors for upgrading could lead to the subset of patients receiving further treatment. In our study, microcalcifications were found in 13.8% cases. Among patients with intraductal papilloma and microcalcifications, 11.8% had DCIS or IC compared with only 0.3% (1/319) of patients with intraductal papilloma and no calcifications (1 pleomorphic LCIS and no DCIS or IC). This result demonstrates that the risk of DCIS or IC is significantly increased in patients with microcalcifications compared with those without microcalcifications. Given that more older patients were observed in the microcalcification group (mean age, 56.0 vs 50.8 years; P = .005) and age could be a risk factor for upgrading, a multivariate analysis adjusted for age was also performed. The results confirmed that microcalcification was a risk factor for upgrading to cancer, independent of age (P = .002). Thus, the presence of microcalcifications may help stratify patients with intraductal papilloma seen on CNB into 2 groups, providing additional management follow-up options. To the best of our knowledge, it is the first observation that microcalcification is an important factor in the management of breast intraductal papillomas diagnosed on CNB.
In conclusion, our study results indicate that surgical excision is required for intraductal papilloma with microcalcifications diagnosed with CNB. However, excision may not be required for patients with intraductal papilloma without microcalcifications and no other known risk factors. We believe that with good radiologic-pathologic correlation, these patients can be treated conservatively. 
